{"created":"2023-06-19T10:30:51.856170+00:00","id":3015,"links":{},"metadata":{"_buckets":{"deposit":"42cb7a63-bcf7-4c8c-9633-df4c04d67d07"},"_deposit":{"created_by":3,"id":"3015","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"3015"},"status":"published"},"_oai":{"id":"oai:kwmed.repo.nii.ac.jp:00003015","sets":["1709617079800:37:801"]},"author_link":["131057","131061","131056","131062","131055","131058","131052","131053","131060","131054","131059"],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2021","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"141","bibliographicPageStart":"131","bibliographicVolumeNumber":"47","bibliographic_titles":[{},{"bibliographic_title":"Kawasaki medical journal","bibliographic_titleLang":"en"}]}]},"item_10001_description_34":{"attribute_name":"記事種別(英)","attribute_value_mlt":[{"subitem_description":"Regular Article","subitem_description_type":"Other"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Kawasaki Medical Society"}]},"item_10001_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.11482/KMJ-E202147131","subitem_relation_type_select":"DOI"}}]},"item_10001_relation_17":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_name":[{}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://igakkai.kms-igakkai.com/wp/wp-content/uploads/2021en/KMJ-E202147131.pdf","subitem_relation_type_select":"URI"}}]},"item_10001_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AA12685295","subitem_source_identifier_type":"NCID"},{"subitem_source_identifier":"AA12029005","subitem_source_identifier_type":"NCID"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"03850234","subitem_source_identifier_type":"ISSN"},{"subitem_source_identifier":"24343404","subitem_source_identifier_type":"ISSN"}]},"item_10001_text_32":{"attribute_name":"著者所属(英)","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"Departments of Nephrology and Hypertension, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Departments of Nephrology and Hypertension, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Departments of Nephrology, Tsukuba Medical Center Hospital"},{"subitem_text_language":"en","subitem_text_value":"Departments of Nephrology and Hypertension, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Departments of Nephrology and Hypertension, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Departments of Nephrology and Hypertension, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Departments of Nephrology and Hypertension, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Departments of Nephrology and Hypertension, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Medical Science, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Departments of Nephrology and Hypertension, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Departments of Nephrology and Hypertension, Kawasaki Medical School"}]},"item_10001_textarea_5":{"attribute_name":"抄録(英)","attribute_value_mlt":[{"subitem_textarea_language":"en","subitem_textarea_value":"　Background: In most developed countries, diabetic kidney disease is the most common cause of chronic kidney disease, leading to end-stage renal disease, and it is also associated with cardiovascular diseases, including heart failure, and a higher risk of other microvascular complications. A recent clinical trial indicated that the dipeptidyl peptidase-4 inhibitor linagliptin prevents the occurrence and progression of albuminuria in patients with type 2 diabetes. Thus, this study aimed to elucidate the molecular mechanism underlying the inhibitory effect of linagliptin on albuminuria in diabetic kidney disease. Methods: Control C57BL/6 mice and diabetic Ins2+/Akita mice were orally administered linagliptin (5 mg/kg/ day) every day for 8 weeks. Results: Compared to control mice, Ins2+/Akita mice had markedly elevated blood glucose and HbA1c levels, but there were no significant changes after linagliptin treatment. Furthermore, albuminuria and urinary 8-OHdG levels were significantly increased and glomerular mesangial area was significantly expanded in Ins2+/Akita mice compared to those in control mice; these changes were ameliorated by linagliptin treatment, which also improved the degradation of glomerular endothelial glycocalyx and enhancement of glomerular permeability of macromolecules. The activity of AMP-activated protein kinase and the expression of guanosine 5'-triphosphate cyclohydrolase I in human glomerular endothelial cells were significantly lower in high glucose conditions and were improved by linagliptin or GLP-1 administration. Discussion: These results together suggest that linagliptin reduced albuminuria in a blood glucose-independent manner via the reduction of oxidative stress and maintenance of the glycocalyx in endothelial cells. Thus, earlier treatment with linagliptin may slow the progression of diabetic kidney disease."}]},"item_10001_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"KONDO, Megumi","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"KIDOKORO, Kengo","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"UCHIDA, Atsushi","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"KADOYA, Hiroyuki","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"UMENO, Reina","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"TOKUYAMA, Atsuyuki","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"WADA, Yoshihisa","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"NAGASU, Hajime","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"KANDA, Eiichiro","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"SASAKI, Tamaki","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"KASHIHARA, Naoki","creatorNameLang":"en"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2022-04-01"}],"displaytype":"detail","filename":"KMJ-E202147131.pdf","filesize":[{"value":"4.5 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"PDF","url":"https://kwmed.repo.nii.ac.jp/record/3015/files/KMJ-E202147131.pdf"},"version_id":"26dc5880-4ac9-4ca6-8d56-2e68882f46c0"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Diabetic kidney disease","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Glucagon-like peptide-1","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Endothelial dysfunction","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Oxidative stress","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Glomerular permeability","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Glycocalyx","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Dipeptidyl peptidase-4 inhibitor linagliptin reduces urinary albumin excretion through the protection of glomerular endothelial function","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Dipeptidyl peptidase-4 inhibitor linagliptin reduces urinary albumin excretion through the protection of glomerular endothelial function","subitem_title_language":"en"}]},"item_type_id":"10001","owner":"3","path":["801"],"pubdate":{"attribute_name":"公開日","attribute_value":"2022-04-01"},"publish_date":"2022-04-01","publish_status":"0","recid":"3015","relation_version_is_last":true,"title":["Dipeptidyl peptidase-4 inhibitor linagliptin reduces urinary albumin excretion through the protection of glomerular endothelial function"],"weko_creator_id":"3","weko_shared_id":-1},"updated":"2023-06-19T10:49:53.012717+00:00"}